PERRIGO Co plc
No enriched coverage for $PRGO in the last 7 days.
No SEC Form 4 filings for $PRGO in the last 30 days.
See all $PRGO insider activity →Perrigo (PRGO) reported weaker Q2 self-care and specialty-care demand in Europe and lower store-brand minoxidil and Mederma comparisons, while U.S. OTC volumes turned positive in late July. Infant formula revenue rose 23% YoY. Core adjusted gross margin fell 250 bps to 37%. Perrigo sold Dermacosmetics for $359M, using proceeds to reduce debt, and reiterated its 2026 outlook, including about -$0.60 EPS from under-absorption.
Perrigo (Q2 2026 earnings call) said core net sales fell 3.1% due to temporary seasonal softness and European retailer destocking, while it gained market share in U.S. store-brand OTC and key European brands. The company maintained full-year 2026 guidance, expects $80m-$100m savings by 2027, and noted a $359m Dermacosmetics divestiture and reviews of Infant Formula and Oral Care.
Biotech stocks rose as several companies reported updates. Attovia Therapeutics (ATTO) jumped over 28% after its Nasdaq debut at $17 and a close at $21.90. American Well (AMWL) gained about 25% after Q2 loss narrowed to $9.6M, though revenue fell to $52.0M. Perrigo (PRGO) swung to Q2 net income of $74.5M. UroGen (URGN) rose after Q2 revenue increased to $72.5M.
Recent PRGO coverage spans earnings, corporate actions and financial news.
Earnings-call details point to near-term margin pressure from volume and mix, partially offset by infant formula profitability and share gains.
Guidance maintenance plus portfolio actions and cost-savings targets frame a clearer path to margin support, with near-term demand normalization signals in U.S. OTC.
The key catalyst is the earnings swing to profit, partially offset by a modest net sales decline.
The earnings beat plus reiterated 2026 EPS guidance is the immediate catalyst driving a relief rally and potentially resetting near-term expectations.
Earnings beat on EPS versus prior-year loss and a reaffirmed FY26 range likely supports near-term sentiment, but weaker sales and lower adjusted EPS guidance range can cap upside.
alphai scores every news story that mentions PRGO with an AI model for sentiment and relevance, and aggregates insider trades from PERRIGO Co plc's SEC EDGAR Form 4 filings. Figures refresh continuously.
Perrigo (PRGO) reported weaker Q2 self-care and specialty-care demand in Europe and lower store-brand minoxidil and Mederma comparisons, while U.S. OTC volumes turned positive in late July. Infant formula revenue rose 23% YoY. Core adjusted gross margin fell 250 bps to 37%. Perrigo sold Dermacosmetics for $359M, using proceeds to reduce debt, and reiterated its 2026 outlook, including about -$0.60 EPS from under-absorption.
4 min readPerrigo (Q2 2026 earnings call) said core net sales fell 3.1% due to temporary seasonal softness and European retailer destocking, while it gained market share in U.S. store-brand OTC and key European brands. The company maintained full-year 2026 guidance, expects $80m-$100m savings by 2027, and noted a $359m Dermacosmetics divestiture and reviews of Infant Formula and Oral Care.
7 min readBiotech stocks rose as several companies reported updates. Attovia Therapeutics (ATTO) jumped over 28% after its Nasdaq debut at $17 and a close at $21.90. American Well (AMWL) gained about 25% after Q2 loss narrowed to $9.6M, though revenue fell to $52.0M. Perrigo (PRGO) swung to Q2 net income of $74.5M. UroGen (URGN) rose after Q2 revenue increased to $72.5M.
3 min readInvesting.com reports Perrigo (PRGO) shares rose 24.4% to $13.41 after the company posted Q2 2026 results above analyst estimates. All-in adjusted diluted EPS was $0.50 versus $0.34 expected, and revenue was about $1.02B versus $1.01B. Perrigo cited cost savings and its Three-S strategy, reaffirmed 2026 EPS guidance, and said €305.6M from the Dermacosmetics sale will aid debt reduction.
4 min readPerrigo Co. plc (PRGO) reported Q2 profit despite lower sales. Net income was $74.5M versus a $8.4M loss a year earlier. EPS was $0.53 versus a loss of $0.06. Net sales fell to $1.02B from $1.06B. Perrigo reaffirmed FY2026 outlook, with adjusted EPS of $2.00 to $2.30. Shares rose about 11% premarket to $12.
2 min readPERRIGO Co plc (PRGO) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 cy26q2ex991pressrelease.htm EX-99.1 Document EXHIBIT 99.1 Perrigo Reports Second Quarter 2026 Financial Results From Continuing Operations • Execution of Three-S plan driving continued improvement in underlying business fundamentals, including market share growth in U.S
6 min readPERRIGO Co plc (PRGO) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. prgo-20260629 0001585364 false 0001585364 2026-06-29 2026-06-29 0001585364 prgo:OrdinaryShares0001ParValueMember 2026-06-29 2026-06-29 0001585364 prgo:A4.900SeniorNoteDue2030Member 2026-06-29 2026-06-29 0001585364 prgo:A6.125SeniorNotesDue2032Member 2026-06-29 2026-06-29 00015853
2 min readPERRIGO Co plc (PRGO) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. prgo-20260630 0001585364 false 0001585364 2026-06-30 2026-06-30 0001585364 prgo:OrdinaryShares0001ParValueMember 2026-06-30 2026-06-30 0001585364 prgo:A4.900SeniorNoteDue2030Member 2026-06-30 2026-06-30 0001585364 prgo:A6.125SeniorNotesDue2032Member 2026-06-30 2026-06-30 00015853
3 min readSimply Wall St discusses governance and strategy risks for Perrigo (PRGO), noting that an extended interim period or CEO search could slow decisions on infant nutrition, cost savings and portfolio moves. It says investors may watch the CEO hire profile and any priority shifts, while Perrigo’s 2026 guidance is described as reaffirmed despite weaker demand and retailer destocking.
5 min readPerrigo Company plc (NYSE: PRGO) said its Board appointed Albert A. Manzone, a current director, as Interim President and CEO effective immediately, and launched a search for a permanent successor. Patrick Lockwood-Taylor resigned as President/CEO and from the Board, after the Board found certain personal conduct inconsistent with the company’s code of conduct. Perrigo reaffirmed its 2026 outlook: All In net sales growth of (5.5)% to (1.5)% and adjusted EPS of $2.00 to $2.30.
4 min read
